written on 21.07.2015
Korea’s Pharmaceutical Spending Compared To OECD Average, 2009 – 2012
Similar Facts and Figures
Top 10 Clinical CROs in Korea
Become a PharmaBoardroom Member for free to access this contentJoin the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password…
Korea’s Health Expenditure Growth Rate 2004 – 2012
Become a PharmaBoardroom Member for free to access this contentJoin the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password…
Korea’s Top Pharma and MedTech Export Destinations
Become a PharmaBoardroom Member for free to access this contentJoin the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password…
Pharma In Korea – In Figures
Become a PharmaBoardroom Member for free to access this contentJoin the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password…
South Korea’s Top Ten Pharma Companies
Become a PharmaBoardroom Member for free to access this contentJoin the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password…
Clinical Trials in Korea: Top Facts
Become a PharmaBoardroom Member for free to access this contentJoin the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password…
Latest Report
APAC / IFPMA's Thomas Cueni on the Value of Business Ethics for SMEs during COVID-19
Drawing on the findings of the Business Ethics for APEC SMEs Initiative, Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) outlines the benefits for small and…
Global / Astellas CMO Bernie Zeiher: Leaving No Stone Unturned in the Quest for Patient Value
Bernie Zeiher, chief medical officer (CMO) of Astellas explains why the ‘patient-defined value’ of medicines is crucial to developing therapies that truly address patients’ unmet medical needs. Zeiher outlines some…
Vaccine Nationalism / “Moral Obscenity, Public Health Catastrophe & Economic Folly”
Over two years since the first cases of COVID-19, the world is still coming to terms with the virus. While vaccines have been developed and rolled out in record time…